CARDIZEM LA Drug Patent Profile
✉ Email this page to a colleague
When do Cardizem La patents expire, and when can generic versions of Cardizem La launch?
Cardizem La is a drug marketed by Bausch and is included in one NDA.
The generic ingredient in CARDIZEM LA is diltiazem hydrochloride. There are twenty-six drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the diltiazem hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cardizem La
A generic version of CARDIZEM LA was approved as diltiazem hydrochloride by TEVA on May 31st, 1995.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CARDIZEM LA?
- What are the global sales for CARDIZEM LA?
- What is Average Wholesale Price for CARDIZEM LA?
Summary for CARDIZEM LA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 131 |
| Clinical Trials: | 10 |
| Patent Applications: | 2,870 |
| Drug Prices: | Drug price information for CARDIZEM LA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for CARDIZEM LA |
| What excipients (inactive ingredients) are in CARDIZEM LA? | CARDIZEM LA excipients list |
| DailyMed Link: | CARDIZEM LA at DailyMed |
See drug prices for CARDIZEM LA
Recent Clinical Trials for CARDIZEM LA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Assiut University | Early Phase 1 |
| CAMC Health System | Phase 4 |
| University of South Florida | N/A |
Pharmacology for CARDIZEM LA
| Drug Class | Calcium Channel Blocker |
| Mechanism of Action | Calcium Channel Antagonists |
Paragraph IV (Patent) Challenges for CARDIZEM LA
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| CARDIZEM LA | Extended-release Tablets | diltiazem hydrochloride | 120 mg, 180 mg, 240 mg, 300 mg and 360 mg | 021392 | 1 | 2005-08-30 |
| CARDIZEM LA | Extended-release Tablets | diltiazem hydrochloride | 420 mg | 021392 | 1 | 2005-04-25 |
US Patents and Regulatory Information for CARDIZEM LA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch | CARDIZEM LA | diltiazem hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021392-001 | Feb 6, 2003 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Bausch | CARDIZEM LA | diltiazem hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021392-004 | Feb 6, 2003 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Bausch | CARDIZEM LA | diltiazem hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021392-002 | Feb 6, 2003 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Bausch | CARDIZEM LA | diltiazem hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021392-003 | Feb 6, 2003 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Bausch | CARDIZEM LA | diltiazem hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021392-006 | Feb 6, 2003 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Bausch | CARDIZEM LA | diltiazem hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021392-005 | Feb 6, 2003 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CARDIZEM LA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch | CARDIZEM LA | diltiazem hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021392-004 | Feb 6, 2003 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch | CARDIZEM LA | diltiazem hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021392-004 | Feb 6, 2003 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch | CARDIZEM LA | diltiazem hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021392-003 | Feb 6, 2003 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch | CARDIZEM LA | diltiazem hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021392-001 | Feb 6, 2003 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch | CARDIZEM LA | diltiazem hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021392-005 | Feb 6, 2003 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch | CARDIZEM LA | diltiazem hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021392-001 | Feb 6, 2003 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch | CARDIZEM LA | diltiazem hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021392-002 | Feb 6, 2003 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CARDIZEM LA
See the table below for patents covering CARDIZEM LA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 9300093 | ⤷ Sign Up | |
| Germany | 60042168 | ⤷ Sign Up | |
| World Intellectual Property Organization (WIPO) | 0141744 | ⤷ Sign Up | |
| European Patent Office | 1235562 | FORMULATIONS A BASE DE DILTIAZEM CHRONOTHERAPEUTIQUES ET LEUR ADMINISTRATION (CHRONOTHERAPEUTIC DILTIAZEM FORMULATIONS AND THE ADMINISTRATION THEREOF) | ⤷ Sign Up |
| European Patent Office | 0591424 | DILTIAZEM SE PRESENTANT SOUS UNE FORME A LIBERATION PROLONGEE (EXTENDED-RELEASE FORM OF DILTIAZEM) | ⤷ Sign Up |
| Australia | 2243092 | ⤷ Sign Up | |
| Australia | 6566700 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
